Show simple item record

dc.contributor.editorBostik, Pavel
dc.contributor.editorKolar, Milan
dc.date.accessioned2022-07-06T11:51:56Z
dc.date.available2022-07-06T11:51:56Z
dc.date.issued2022
dc.identifierONIX_20220706_9783036544182_79
dc.identifier.urihttps://directory.doabooks.org/handle/20.500.12854/87484
dc.description.abstractBacterial resistance to known and currently used antibiotics represents a growing issue worldwide. It poses a major problem in the treatment of infectious diseases in general and hospital-acquired infections in particular. This is in part due to the overuse and misuse of antibiotics in past decades, which led to the selection of highly resistant bacteria and even so-called superbugs – multidrug-resistant (MDR) bacteria. Nosocomial infections, particularly, are often caused by MDR bacterial pathogens and the treatment of such infections is very complicated and extensive, often leading to various side effects, including adverse effects on the natural human microbiome. At the same time, the development of novel antibiotics is lagging with very few new ones in the pipeline. Finding viable alternatives to treat such infections may help to overcome these therapeutic issues. This publication brings novel developments in the field of bacterial resistance, mainly in the hospital settings, adequate antibiotic therapy, and identification of compounds useful to battle this growing issue.
dc.languageEnglish
dc.subject.classificationthema EDItEUR::M Medicine and Nursingen_US
dc.subject.classificationthema EDItEUR::M Medicine and Nursing::MB Medicine: general issues::MBN Public health and preventive medicine::MBNS Epidemiology and Medical statisticsen_US
dc.subject.otherVRE
dc.subject.otherGIT
dc.subject.otherhemato-oncological patients
dc.subject.otherclonality
dc.subject.otherantibiotic stewardship
dc.subject.otherresistance
dc.subject.otherconsumption of antibiotics
dc.subject.otherclonal spread
dc.subject.otherEnterococcus faecium
dc.subject.otherEnterococcus faecalis
dc.subject.otherlinezolid resistance
dc.subject.other23S rRNA
dc.subject.otheroptrA
dc.subject.othercarbapenem-resistant Klebsiella pneumoniae
dc.subject.othercarbapenem-resistant Acinetobacter baumannii
dc.subject.otherN-acetylcysteine
dc.subject.otherseptic shock
dc.subject.othercritically ill patients
dc.subject.othernewborn
dc.subject.otherinfection
dc.subject.otherbacteria
dc.subject.otherantibiotic therapy
dc.subject.otherhops
dc.subject.otherC. difficile
dc.subject.otherrat model
dc.subject.otherStaphylococcus aureus
dc.subject.otherMRSA
dc.subject.otherspa typing
dc.subject.otherMLST
dc.subject.otherSCCmec typing
dc.subject.otherclonal analysis
dc.subject.otherepidemiology
dc.subject.othercancer patients
dc.subject.otherduration of treatment
dc.subject.othercolistin
dc.subject.otherpropensity score analysis
dc.subject.othermultidrug-resistant Acinetobacter baumannii
dc.subject.otherurinary tract infections
dc.subject.otherUTIs
dc.subject.otherMDR
dc.subject.otherEscherichia coli
dc.subject.otherKlebsiella
dc.subject.otheruropathogens
dc.subject.otherAMR
dc.subject.otherantibiotic resistance
dc.subject.otherESBL-producing Klebsiella pneumoniae
dc.subject.otherurinary tract infection
dc.subject.otherclinical impact
dc.subject.othereconomic impact
dc.subject.otherventilator-associated pneumonia
dc.subject.otherKlebsiella spp.
dc.subject.otherEscherichia spp.
dc.subject.otherpulsed-field gel electrophoresis (PFGE)
dc.subject.otherendogenous infection
dc.subject.othermethicillin-resistant
dc.subject.otherporcine model
dc.subject.othermethicillin-resistant Staphylococcus aureus (MRSA)
dc.subject.otherlong term care facilities (LTCF)
dc.subject.othermultidrug resistance (MDR)
dc.subject.otherenterobacterial repetitive intergenic consensus-polymerase chain reaction (ERIC-PCR)
dc.subject.otherESBL
dc.subject.otherPCR
dc.subject.otherprimer
dc.subject.otherantimicrobial resistance
dc.subject.otherinfection prevention and control
dc.subject.otherantimicrobial stewardship
dc.subject.otherhospital
dc.subject.othercluster analysis
dc.subject.otherprincipal component analysis
dc.titleHospital Acquired Infections, Multidrug Resistant (MDR) Bacteria, Alternative Approaches to Antibiotic Therapy
dc.typebook
oapen.identifier.doi10.3390/books978-3-0365-4417-5
oapen.relation.isPublishedBy46cabcaa-dd94-4bfe-87b4-55023c1b36d0
oapen.relation.isbn9783036544182
oapen.relation.isbn9783036544175
oapen.pages206
oapen.place.publicationBasel


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0/